Immune-Guided Strategy Reduces CMV Disease in Kidney Transplant Recipients

Cytomegalovirus remains a frequent and significant complication following kidney transplantation, often correlating with adverse outcomes such as graft rejection, increased risk of opportunistic fungal infections, and higher mortality rates [1, 2]. While universal antiviral prophylaxis and preemptive therapy are established strategies to mitigate these risks, the optimal approach for intermediate-risk recipients, specifically those who are already seropositive, remains a subject of clinical debate [3, 4]. Current protocols often rely on static risk factors, yet the dynamic nature of a patient's cellular immune response is a critical determinant of their ability to control viral replication [5]. Emerging evidence suggests that monitoring specific cell-mediated immunity (the functional ability of T-cells to recognize and respond to a pathogen) may offer a more personalized path to managing viral risk [6]. A new study now evaluates whether an immune-guided strategy based on early functional assays can refine these preventive efforts in the clinical setting.